Clinical Trials
27 trialsA Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
Roswell Park Cancer Institute
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer
Memorial Sloan Kettering Cancer Center
Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC
University of Iowa
ENHANCE
Hoosier Cancer Research Network
BicaBCa
CHU de Quebec-Universite Laval
GEMDOCE
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients
Peking University First Hospital
COBRA
Medical University of Vienna
eRapa
The University of Texas Health Science Center at San Antonio
The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer
A.O.U. Città della Salute e della Scienza
A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk.
Fujian Medical University Union Hospital
BRAVE
University of Alberta
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
Fudan University
POLO
University of Bern
TROJAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Efficacy and Safety of Pseudomonas Aeruginosa for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Qilu Hospital of Shandong University
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
RenJi Hospital
RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer
West China Hospital
Intravesical Electromotive Mitomycin After Bacillus Calmette-Guérin Failure
University of Rome Tor Vergata
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Sir Mortimer B. Davis - Jewish General Hospital
PREVERT
Institut Paoli-Calmettes
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
IPOI vs IPOP
Poitiers University Hospital
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
University of Rome Tor Vergata
Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari